Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
Provided By GlobeNewswire
Last update: Sep 5, 2025
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~
Read more at globenewswire.com37.16
-1.4 (-3.63%)
Find more stocks in the Stock Screener
MLYS Latest News and Analysis
